About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Care Pathways for Benchmarking on Fragile Hip Fractures Rapid Recovery

Clinicaltrials.gov identifier NCT03941353

Recruitment Status Enrolling by invitation

First Posted May 7, 2019

Last update posted July 21, 2020

Study Description

Brief summary:

The aim of this project is to build an international community of centers of excellence in the care for Fragile Hip Fracture Rapid Recovery patients. These centers of excellence will benchmark and share their expertise and experiences based on clinical and managerial data. In project is designed in five different phase: Phase 1: literature review: identifying relevant key interventions and indicators Phase 2: expert panel: expert panel for teams, management and policy makers Phase 3: data collection: collection managerial data through retrospective patient record analysis on clinical indicators Phase 4: statistical data analysis: data input, validation and statistical analysis Phase 5: feedback and knowledge sharing: feedback report with anonymous benchmarking and knowledge sharing of the results.

  • Condition or Disease:Quality Improvement
    Hip Fractures
  • Intervention/Treatment: Other: Usual care
  • Phase: N/A
Detailed Description

N/A

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 1500 participants
  • Observational Model: Cohort
  • Time Perspective: Retrospective
  • Official Title: Care Pathways for Benchmarking on Fragile Hip Fractures Rapid Recovery
  • Actual Study Start Date: January 2020
  • Estimated Primary Completion Date: June 2020
  • Actual Study Completion Date: October 2020
Outcome Measures
  • Primary Outcome Measures: 1. Performance on quality indicators at patient level (Quality of Care and patient satisfaction) for patients admitted with a fragile hip fracture. [ Time Frame: through study completion, an average of 1 year ]
    This study evaluates quality indicators at patient level as defined by the expert panel to determine appropriateness of fragile hip fracture indicators. The indicators will cover the pre-operative, peri-operative and post-operative care process. The data will be selected out of the patient record. Based on the expert panel quality of care is measured by time to surgery, information on pre-fall cognitive status, information on pre-fall mobility status, fasting time, administration of carbohydrate loading, administration of cortical steriods, use of tranexamic acid, urinary catheterization, administration of pain medication, time to post operative surgeon note for care team, time of drain duration, type of anesthesia, measurement of haemoglobin, mobilisation post-operative, following of pain protocol, plan for discharge, nutrition supplementation. he study is limited to the period in which the patients are hospitalized. No data is gathered before or after hospitalization.
Eligibility Criteria
  • Ages Eligible for Study: 65 Years and older (Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patient admitted with a proximal femur fracture
Criteria

Inclusion Criteria:

- Trauma related non-elective admission for hip fracture;

- Minimum age of 65 years;

- The following hip fractures are included: Femoral neck, femoral head, trochanteric and
subtrochanteric fractures;

- Discharged or deceased before May 30th of 2019

Exclusion Criteria:

- Hip fracture is not the main reason for admission to emergency room;

- Additional ipsilateral fractures;

- Hip fracture resulting from in-hospital fall that occurred in the hospital where the
patient receives hip fracture care.

Contacts and Locations
Contacts
Locations

Belgium
KU Leuven
Leuven

Sponsors and Collaborators

European Pathway Association

KU Leuven

More Information
  • Responsible Party: European Pathway Association
  • ClinicalTrials.gov Identifier: NCT03941353 History of Changes
  • Other Study ID Numbers: CP4FHF
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: July 21, 2020
  • Last Verified: July 2020
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Fractures, Bone Hip Fractures